Comparative Pharmacology
Head-to-head clinical analysis: TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE versus VYLOY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE versus VYLOY.
TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE vs VYLOY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trifluridine is a thymidine-based nucleoside analog that incorporates into DNA, interfering with DNA synthesis and function. Tipiracil hydrochloride inhibits thymidine phosphorylase, preventing trifluridine degradation and increasing its systemic exposure.
VYLOY (zolbetuximab-clzb) is a chimeric IgG1 monoclonal antibody that binds to claudin 18.2 (CLDN18.2), a tight junction protein expressed on the surface of gastric cancer cells. Binding induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to tumor cell death.
35 mg/m² orally twice daily on days 1-5 and 8-12 of each 28-day cycle. Maximum dose: 80 mg per dose.
VYLOY (zolbetuximab-clzb) is administered intravenously at a dose of 800 mg every 2 weeks following a loading dose of 1200 mg on day 1 of cycle 1.
None Documented
None Documented
The terminal elimination half-life of trifluridine is approximately 1.4 to 2.1 hours. For tipiracil, the half-life is about 2.1 to 3.3 hours. The short half-lives necessitate twice-daily dosing to maintain therapeutic concentrations.
Approximately 2.2 hours (terminal elimination half-life); clinical context: supports twice-weekly dosing schedule.
Trifluridine is primarily eliminated via metabolism and renal excretion. Approximately 29% of the trifluride dose is recovered in urine as trifluridine and its metabolites, with less than 3% as unchanged drug. Fecal excretion accounts for about 38% of the dose, mainly as metabolites. Tipiracil is predominantly excreted renally (about 55% as unchanged drug and metabolites) and fecally (about 19%).
Primarily hepatobiliary excretion into feces; minimal renal elimination (<1% unchanged in urine).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent